Teriparatide and osseous regeneration in the oral cavity

New England Journal of Medicine

Volumn 363, Issue 25, 2010, Pages 2396-2405

  Bashutski, Jill D ^a,b   Eber, Robert M ^a,b   Kinney, Janet S ^a,b   Benavides, Erika ^a   Maitra, Samopriyo ^b   Braun, Thomas M ^b   Giannobile, William V ^a,b   McCauley, Laurie K ^a,b,c  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE[1-34]; PLACEBO; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ADULT; ALVEOLAR BONE; ARTICLE; BONE DENSITY; BONE REGENERATION; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE HEALING; HUMAN; MALE; MOUTH CAVITY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PARALLEL DESIGN; PERIODONTITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 78650184681     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1005361     Document Type: Article

References (40)

1. Curtis JW Jr. Infections associated with diabetes mellitus. N Engl J Med 2000; 342:895-6.
2. Michalowicz BS, Hodges JS, DiAngelis AJ, et al. Treatment of periodontal disease and the risk of preterm birth. N Engl J Med 2006;355:1885-94.
3. Tonetti MS, D'Aiuto F, Nibali L, et al. Treatment of periodontitis and endothelial function. N Engl J Med 2007;356:911-20.
4. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet 2005;366:1809-20.
5. Offenbacher S, Beck JD, Moss K, et al. Results from the Periodontitis and Vascular Events (PAVE) Study: a pilot multi-centered, randomized, controlled trial to study effects of periodontal therapy in a secondary prevention model of cardiovascular disease. J Periodontol 2009;80:190-201.
6. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010;25:404-14.
7. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-53.
8. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
9. Barros SP, Silva MA, Somerman MJ, Nociti FH Jr. Parathyroid hormone protects against periodontitis-associated bone loss. J Dent Res 2003;82:791-5.
10. Schneider A, Taboas JM, McCauley LK, Krebsbach PH. Skeletal homeostasis in tissue-engineered bone. J Orthop Res 2003; 21:859-64.
11. Jung RE, Cochran DL, Domken O, et al. The effect of matrix bound parathyroid hormone on bone regeneration. Clin Oral Implants Res 2007;18:319-25.
12. Duckworth JE, Judy PF, Goodson JM, Socransky SS. A method for the geometric and densitometric standardization of intraoral radiographs. J Periodontol 1983;54: 435-40.
13. Reddy MS, Jeffcoat MK. Digital subtraction radiography. Dent Clin North Am 1993;37:553-65.
14. Giannobile WV, Lynch SE, Denmark RG, Paquette DW, Fiorellini JP, Williams RC. Crevicular fluid osteocalcin and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as markers of rapid bone turnover in perio dontitis: a pilot study in beagle dogs. J Clin Periodontol 1995;22:903-10.
15. Slade GD, Spencer AJ. Development and evaluation of the Oral Health Impact Profile. Community Dent Health 1994;11: 3-11.
16. Sculean A, Berakdar M, Donos N, Auschill TM, Arweiler NB. The effect of postsurgical administration of a selective cyclo-oxygenase-2 inhibitor on the healing of intrabony defects following treatment with enamel matrix proteins. Clin Oral Investig 2003;7:108-12.
17. Pihlstrom BL, Oliphant TH, McHugh RB. Molar and nonmolar teeth compared over 6 1/2 years following two methods of periodontal therapy. J Periodontol 1984; 55:499-504.
18. Isidor F, Karring T. Long-term effect of surgical and non-surgical periodontal treatment: a 5-year clinical study. J Periodontal Res 1986;21:462-72.
19. Heitz-Mayfield LJ, Trombelli L, Heitz F, Needleman I, Moles D. A systematic review of the effect of surgical debridement vs non-surgical debridement for the treatment of chronic periodontitis. J Clin Periodontol 2002;29:Suppl 3:92-102, 160-2.
20. Bhongade ML, Tiwari IR. A comparative evaluation of the effectiveness of an anorganic bone matrix/cell binding peptide with an open flap debridement in human infrabony defects: a clinical and radiographic study. J Contemp Dent Pract 2007;8:25-34.
21. Gapski R, Hasturk H, Van Dyke TE, et al. Systemic MMP inhibition for periodontal wound repair: results of a multicentre randomized-controlled clinical trial. J Clin Periodontol 2009;36:149-56.
22. Dybvik T, Leknes KN, Bøe OE, Skavland RJ, Albandar JM. Bioactive ceramic filler in the treatment of severe osseous defects: 12-month results. J Periodontol 2007;78:403-10.
23. Laurell L, Gottlow J, Zybutz M, Persson R. Treatment of intrabony defects by different surgical procedures: a literature review. J Periodontol 1998;69:303-13.
24. Shirakata Y, Setoguchi T, Machigashira M, et al. Comparison of injectable calcium phosphate bone cement grafting and open flap debridement in periodontal intrabony defects: a randomized clinical trial. J Periodontol 2008;79:25-32.
25. Gapski R, Barr JL, Sarment DP, Layher MG, Socransky SS, Giannobile WV. Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: a proof of concept trial. J Periodontol 2004;75:441-52.
26. Heijl L, Heden G, Svärdström G, Ostgren A. Enamel matrix derivative (EMDOGAIN) in the treatment of intrabony periodontal defects. J Clin Periodontol 1997;24:705-14. (Pubitemid 127731614)
27. Kitamura M, Nakashima K, Kowashi Y, et al. Periodontal tissue regeneration using fibroblast growth factor-2: randomized controlled phase II clinical trial. PLoS One 2008;3(7):e2611.
28. Nevins M, Giannobile WV, McGuire MK, et al. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial. J Periodontol 2005;76:2205-15.
29. Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 2008;42:806-18.
30. El-Shinnawi UM, El-Tantawy SI. The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). J Int Acad Periodontol 2003;5:5-10.
31. Graziani F, Cei S, Guerrero A, et al. Lack of short-term adjunctive effect of systemic neridronate in non-surgical periodontal therapy of advanced generalized chronic periodontitis: an open label-randomized clinical trial. J Clin Periodontol 2009;36:419-27.
32. Jeffcoat MK, Cizza G, Shih WJ, Genco R, Lombardi A. Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis. J Int Acad Periodontol 2007;9:70-6.
33. Lane N, Armitage GC, Loomer P, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol 2005;76:1113-22.
34. Rocha ML, Malacara JM, Sánchez- Marin FJ, Vazquez de la Torre CJ, Fajardo ME. Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial. J Periodontol 2004;75:1579-85.
35. Takaishi Y, Ikeo T, Miki T, Nishizawa Y, Morii H. Suppression of alveolar bone resorption by etidronate treatment for periodontal disease: 4- to 5-year followup of four patients. J Int Med Res 2003; 31:575-84.
36. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
37. Lau AN, Adachi JD. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol 2009;36:1835-7.
38. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH (1-34)]. J Oral Maxillofac Surg 2007;65:573-80.
39. Tsiridis E, Morgan EF, Bancroft JM, et al. Effects of OP-1 and PTH in a new experimental model for the study of metaphyseal bone healing. J Orthop Res 2007;25:1193-203.
40. Jung RE, Hämmerle CH, Kokovic V, Weber FE. Bone regeneration using a synthetic matrix containing a parathyroid hormone peptide combined with a grafting material. Int J Oral Maxillofac Implants 2007;22:258-66.